2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroup
2020
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsHematologic NeoplasmsHumansIncidenceMyeloproliferative DisordersPrognosisRisk FactorsSurvival AnalysisConceptsChronic myeloid leukemiaPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsClassical myeloproliferative neoplasmsPrimary myelofibrosisIncidence of CMLEnd Results program dataTyrosine kinase inhibitor therapyCML patient outcomesClonal myeloid disordersKinase inhibitor therapyPotential etiological roleInhibitor therapyMale genderRisk factorsPatient outcomesMyeloid leukemiaPMF patientsBetter survivalGeneral populationEtiological roleMyeloid disordersMolecular abnormalitiesEpidemiological literatureReply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. International Journal Of Cancer 2020, 146: 3523-3523. PMID: 32167580, PMCID: PMC8915778, DOI: 10.1002/ijc.32974.Commentaries, Editorials and LettersLifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.Peer-Reviewed Original ResearchConceptsNIH-AARP DietPolycythemia veraMyeloproliferative neoplasmsEssential thrombocythemiaHazard ratioLifestyle factorsCaffeine intakeHealth StudyMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRisk of PVProportional hazards regression modelsRisk of MPNLarge prospective studiesHazards regression modelsConfidence intervalsPhiladelphia chromosome-negative myeloproliferative neoplasmsMPN riskOverall cohortProspective cohortProspective studyInverse associationRisk factorsPV riskProtective effect
2019
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma 2018, 60: 246-249. PMID: 29963936, DOI: 10.1080/10428194.2018.1468893.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTransplantation, HomologousTreatment OutcomeYoung Adult
2014
Marrow Assessment for Hemophagocytic Lymphohistiocytosis Demonstrates Poor Correlation With Disease Probability
Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow Assessment for Hemophagocytic Lymphohistiocytosis Demonstrates Poor Correlation With Disease Probability. American Journal Of Clinical Pathology 2014, 141: 62-71. PMID: 24343738, DOI: 10.1309/ajcpmd5tjefoovbw.Peer-Reviewed Original ResearchConceptsFindings of hemophagocytosisHemophagocytic lymphohistiocytosisHistologic findingsProbability of HLHSecondary hemophagocytic lymphohistiocytosisCore biopsy specimenCore biopsy specimensDisease probabilityFisher's exact testElevated ferritinClinical suspicionMarrow assessmentHLH groupBiopsy specimenLaboratory criteriaBiopsy specimensMedical recordsHemophagocytosisExact testLymphohistiocytosisPatientsSignificant correlationAspiratesPoor correlationFindings